<DOC>
	<DOC>NCT02349399</DOC>
	<brief_summary>The study objectives are to characterize new users of Cyproterone Acetate / Ethinylestradiol (CPA/EE) in 2011/2012 and in 2014 according to demographics, treatment characteristics, previous diagnosis of acne, hirsutism or other hyperandrogenic conditions, previous acne treatment and (concomitant) use of hormonal contraceptives identified in Healthcare Databases in the UK (THIN), the Netherlands (PHARMO) and Italy (HSD).</brief_summary>
	<brief_title>Drug Utilization Study on Diane-35 (and Generics) in Three European Healthcare Databases</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Cyproterone acetate, ethinyl estradiol drug combination</mesh_term>
	<mesh_term>Cyproterone</mesh_term>
	<mesh_term>Cyproterone Acetate</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<criteria>The study population will include all female patients registered in the investigated healthcare databases receiving CPA/EE in 2011 or 2012 (first run) or 2014 (second run), without a prescription of CPA/EE in the year prior to index date. Only patients with recorded history in the database of â‰¥ 365 days prior to index date will be included in the study. &lt;365 days recorded history in the database prior to index date a prescription of CPA/EE in the year prior to index date</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>